Linked Life Data

6660435

Source:http://linkedlifedata.com/resource/pubmed/id/6660435

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
1984-2-14
pubmed:abstractText
Twenty-six pollen-allergic subjects participated in a double-blind, placebo-controlled trial of the protective effect of the calcium antagonist, verapamil, on allergen-provoked nasal symptoms. Intranasal verapamil, 1 mg. had a weak protective effect in that "tickling score" was 22% lower (P less than 0.01) and the number of sneezes 29% lower (nonsignificant) after verapamil as compared with placebo pretreatment. There were no differences with regard to nasal blockage or discharge. It is concluded that the verapamil spray used, cannot be recommended for clinical trials, but that further investigations of other formulations of calcium antagonist are justified in order to analyse the potential role of this type of drugs in the treatment of allergic rhinitis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0105-4538
pubmed:author
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
565-70
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
1983
pubmed:articleTitle
Intranasal verapamil in allergen-induced rhinitis.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't